ST LOUIS--(BUSINESS WIRE)--PierianDx, the leading genomics technology company that enables precision medicine, named Chris Callahan as the new Chief Commercial Officer to accelerate adoption and expansion of the company’s enterprise informatics software platform, the Clinical Genomics WorkSpace (CGW). Chris will report to PierianDx CEO Rakesh Nagarajan, M.D., Ph.D., and oversee customer success, sales, marketing, and business development.
“Chris brings a wealth of experience and the proven ability to expand market share for companies in our industry,” said Nagarajan. “Bringing Chris onboard is part of our overall growth plan to advance our platform into new markets. We are excited to have him on the team.”
Callahan has been in the healthcare information technology arena since 2000, when he served as Senior Manager of Business Development for Cerner Corporation. Most recently, he served as Vice President of Product Strategy and Business Development at Sunquest Information Systems, where he helped to drive corporate growth and acquisitions, which included the general management, strategic direction and growth of GeneInsight.
“PierianDx has been accelerating precision medicine for some of the most advanced health systems, cancer centers and academic medical centers in the world,” said Callahan. “I am honored to be a part of PierianDx’s growth and momentum.”
Callahan lives outside of Raleigh, North Carolina, and holds a Master’s degree in Management from the Kellogg School of Management.
PierianDx is the leading genomics technology provider that enables precision medicine programs for healthcare organizations by offering solutions to accelerate molecular testing and results delivery. We do this by producing Actionable Intelligence™ through our workflow and analysis software, Clinical Genomics WorkSpace™, that is driven by a constantly learning knowledgebase and deep clinical expertise. The resulting data visualization and easy-to-understand reports are used to deliver patient-specific diagnosis and treatments for somatic and inherited diseases based on an individual’s DNA and RNA. Since being founded by scientists, clinicians and bioinformatics experts in 2014, PierianDx has expanded its partner network to include leading health systems, academic medical centers, cancer centers, children’s hospitals, and commercial labs.
Please visit www.pieriandx.com or @PierianDx on Twitter.